LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

European Bioeconomy Alliance (EUBA) comments on the European Climate Law Roadmap

12/02/2020
OTHER

European Bioeconomy Alliance (EUBA) comments on the European Climate Law Roadmap

The European Bioeconomy Alliance (EUBA), representing 12 leading European organisations in various sectors active in the bioeconomy, welcomes that the European Green Deal puts reduction of greenhouse gas emissions as a key priority. In this context and in view of the forthcoming Climate Law, the transition to a circular bioeconomy is a major opportunity to create competitive advantages for Europe and, as the updated EU Bioeconomy Strategy underlines “[a] sustainable European bioeconomy is necessary to build a carbon neutral future in line with the Climate objectives of the Paris Agreement”.

The bioeconomy is already worth more than €2 trillion annually and employs over 18 million Europeans. Given the right conditions and a stable investment and policy environment, the bioeconomy can help reduce reliance on resources of fossil origin, boost competitiveness and job creation, and contribute to policy goals and initiatives, including in the fields of climate and sustainability. EUBA agrees with the aim as outlined in the Climate Law Roadmap to ensure that that all sectors play their part, that all relevant policies should contribute to reaching the climate goals and that this amongst other things includes strengthening incentives for developing climate-friendly and sustainable practices, products and technologies.

The European Commission’s strategic long-term vision for 2050 “A Clean Planet for all” identified the bioeconomy as one of the seven strategic areas requiring joint action on the road to a climate neutral economy. In doing so, it sends a clear signal that Europe needs more than ever to boost its bioeconomy sectors if it wants the strategy to become a reality. The switch towards a circular bio-based economy, as pointed out in the Communication strategic building blocks, has the potential to play a leading role in pursuing climate ambitions of the EU.

Replacing finite materials with materials from renewable sources can help sustain material supply, keep natural resources in the economic cycle and minimise the extraction of finite raw materials. Also, as outlined in an OECD report “[…] the full climate change mitigation potential of biotechnology processes and bio-based products ranges from between 1 billion and 2.5 billion tons CO2 equivalent per year by 2030”. Instead of releasing historic carbon into the atmosphere through fossil fuel extraction and use, the carbon in bio-based products is the product of atmospheric CO2 and water. When this biomass is then used to make bio-based products, the atmospheric CO2 remains trapped in the products throughout their lifespan.

The bioeconomy encompasses the sustainable production of renewable biological resources from land and sea and their conversion into vital products and bioenergy with the help of innovative technologies. It can help deliver a more competitive, dynamic and sustainable European economy by valorising non-fossil carbon to substitute fossil-based raw materials and more carbon-intensive products and production processes.

European Bioeconomy Alliance (EUBA) comments on the European Climate Law Roadmap


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

22/05/2025

Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World


Read more
21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
10/04/2025

EU biotechnology competitiveness for the future; high level dialogue with EVP Séjourné


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.